

**WPD Pharmaceuticals (CSE:WBIO FRA: 8SV1)** is a diverse biotech company focused on oncology and virology. WPD has secured exclusive rights (worldwide or for specific territories) for several novel anticancer and antiviral drug candidates in either advanced preclinical or clinical stage development. Licensed drug candidates were discovered and studied at premier USA research institutions such as MD Anderson Cancer Center, Mayo Clinic, Emory University, Wake Forest Comprehensive Cancer Center and leading Institutes, hospitals and academic centers in Poland.

WPD was envisioned as a continuous and active international collaborator with other leading drug developers. The Company has initially focused on combining efforts between Poland and partners in the USA to target diseases without effective therapeutic options. WPD's licensed innovations include three highly promising biological products at the pre-clinical stage (worldwide license) and four clinical stage drugs (license in selected territories) including international cooperation with two NASDAQ companies, Moleculin Biotech and CNS Pharmaceuticals. WPD's team is highly experienced in clinical studies and capable of supporting pharmaceutical product development on a stand-alone basis or as co-development partners. WPD is well prepared and organized to create and implement clinical development strategies, including interaction with the EMA and other regulatory bodies, as well as CRO and programs supervision.

Alongside direct investment of \$71 million, over \$29 million of grant funding (total of \$100 million USD by licensors) has been applied towards the development of WPD's robust drug development pipeline with focus on antiviral drugs (including those targeting COVID-19) and anticancer drugs targeting, among others, primary and metastatic brain cancers, leukemia, sarcoma, melanoma, and pancreatic cancer. Independently, \$14 million USD in grants was recently awarded to WPD Pharmaceuticals from The National Center for Research and Development in Poland for preclinical and clinical development of drugs targeting highly resistant cancers.

With a groundswell of multi-continental grant support and a diverse portfolio of breakthrough drug technologies, WPD Pharmaceuticals is now strategically positioned to make significant progress.

## COMPANY HIGHLIGHTS

- Collaborative Bridge Between Poland and USA**  
 Exclusive licence agreement for WPD101 family of products and licensed market-sharing co-developmental projects with USA companies initially benefiting patients in Poland and USA.
- Distinct Business Model**  
**(A)** Acquiring exclusive worldwide rights to highly innovative products in advanced preclinical stage of their development. **(B)** Licensing territorial rights to clinical stage drugs and close clinical development cooperation with the licensor. **(C)** Providing clinical development services for international companies in Poland.
- Experienced Management and Advisors**  
 Distinguished team of scientists with extensive drug development experience.
- Robust Drug Portfolio**  
 Seven highly innovative anticancer and antiviral drug candidates under development.

- Strategic International Partnerships**  
 Wake Forest University Health Sciences (US), Moleculin Biotech, Inc. (Nasdaq: MBRX) and CNS Pharmaceuticals, Inc. (Nasdaq: CNSP).
- Strategic Partnerships with Scientists and Clinical Centers in Poland and Europe**  
 WPD is well positioned to organize and support active clinical research in Poland for itself and for international companies.
- Rapidly Growing Operations**  
 Four drug candidates in clinical trials, including Berubicin (Phase 2 trials commencing in Q1 2021), WP1066 (Phase 1), Annamycin (Phase 1), WP1220 (Phase 1).
- Attractive Valuation**  
 Discount to industry peers.

## KEY DRUG CANDIDATES

### WPD101

Targeted biopharmaceutical therapy of brain cancer glioblastoma multiforme (GBM). Successfully tested in dogs with spontaneous GBM. Currently in advanced preclinical development. License Agreement with Wake Forest University of Health Sciences (WFUHS).

### Berubicin

Phase I clinical study showed promising therapeutic effects in GBM patients with one complete response. Sublicensed from CNS Pharmaceuticals, Inc.

### Annamycin

Two independent clinical studies to treat AML and lung metastatic cancers. Phase 1 ongoing in Poland. Sublicensed from Moleculin Biotech, Inc.

### WP1066

STAT3 inhibitor already in Phase 1 clinical studies in brain cancers in USA. Sublicensed from Moleculin Biotech, Inc.

### WP1220

STAT3 inhibitor designed for topical administration with Phase 1 pilot study completed in Poland. Sublicensed from Moleculin Biotech, Inc.

## COMPANY SNAPSHOT

### CSE:WBIO; FRA:8SV1

Issued & outstanding	113,438,244
Options	7,975,000
Warrants	2,357,142
Fully Diluted	123,770,386
Insider Holdings	~35%